PURPOSE: To redefine the clinical remission period for different aged children receiving the current standard of diabetes care. METHODS: An electronic patient records system was used to identify 552 children newly diagnosed with type 1 diabetes (T1D) from 1997 to 2001 who had an initial hemoglobin A1c (HbA1c) value at the time of diagnosis and at least one other value measured in the ensuing year. The insulin dosage previously used to define the remission period [<0.5 units per kg body weight per day (U/kg/d)] was evaluated for the different aged children. RESULTS: The mean insulin dosages for all age groups were >0.5 U/kg/d by 9 months after diagnosis. The mean HbA1c values were above 8% by 6 months after diagnosis for the 6-9 and the 10-12 yr age groups and by 9 months after diagnosis for the >or=13 yr age group. The percentage of children <or=5 yr of age who continued to receive <0.5 U/kg/d of insulin was higher than for the other three age groups. However, this group did not achieve a mean HbA1c value <8% at any time. CONCLUSION: Older children have a longer remission period than younger children. The clinical definition of the remission period should be redefined to include both the insulin dose and the HbA1c level. Any attempt to extend the remission period in children is more apt to be successful in dealing with older children and with the introduction of the intervention as soon after diagnosis as is feasible.
PURPOSE: To redefine the clinical remission period for different aged children receiving the current standard of diabetes care. METHODS: An electronic patient records system was used to identify 552 children newly diagnosed with type 1 diabetes (T1D) from 1997 to 2001 who had an initial hemoglobin A1c (HbA1c) value at the time of diagnosis and at least one other value measured in the ensuing year. The insulin dosage previously used to define the remission period [<0.5 units per kg body weight per day (U/kg/d)] was evaluated for the different aged children. RESULTS: The mean insulin dosages for all age groups were >0.5 U/kg/d by 9 months after diagnosis. The mean HbA1c values were above 8% by 6 months after diagnosis for the 6-9 and the 10-12 yr age groups and by 9 months after diagnosis for the >or=13 yr age group. The percentage of children <or=5 yr of age who continued to receive <0.5 U/kg/d of insulin was higher than for the other three age groups. However, this group did not achieve a mean HbA1c value <8% at any time. CONCLUSION: Older children have a longer remission period than younger children. The clinical definition of the remission period should be redefined to include both the insulin dose and the HbA1c level. Any attempt to extend the remission period in children is more apt to be successful in dealing with older children and with the introduction of the intervention as soon after diagnosis as is feasible.
Authors: Renecia A Watkins; Carmella Evans-Molina; Jennifer K Terrell; Kathleen H Day; Lynette Guindon; Ivan A Restrepo; Raghavendra G Mirmira; Janice S Blum; Linda A DiMeglio Journal: Transl Res Date: 2015-09-04 Impact factor: 7.012
Authors: S Glisic-Milosavljevic; T Wang; M Koppen; J Kramer; S Ehlenbach; J Waukau; P Jailwala; S Jana; R Alemzadeh; S Ghosh Journal: Clin Exp Immunol Date: 2007-08-17 Impact factor: 4.330
Authors: Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone Journal: Clin Immunol Date: 2009-05-14 Impact factor: 3.969
Authors: Eda Cengiz; Crystal G Connor; Katrina J Ruedy; Roy W Beck; Craig Kollman; Georgeanna J Klingensmith; William V Tamborlane; Joyce M Lee; Michael J Haller Journal: Pediatr Diabetes Date: 2013-08-15 Impact factor: 4.866
Authors: Henrik B Mortensen; Philip Hougaard; Peter Swift; Lars Hansen; Reinhard W Holl; Hilary Hoey; Hilde Bjoerndalen; Carine de Beaufort; Francesco Chiarelli; Thomas Danne; Eugen J Schoenle; Jan Aman Journal: Diabetes Care Date: 2009-05-12 Impact factor: 17.152